Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study-Reference-Cited by-同舟云学术

Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study

Published:2021-02-08 Issue: Volume: Page:1-9
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Beck Lisa A.¹^ORCID,Thaçi Diamant²^ORCID,Deleuran Mette³^ORCID,de Bruin-Weller Marjolein⁴,Chen Zhen⁵,Khokhar Faisal A.⁵,Zhang Meng⁶,Ozturk Zafer E.⁷,Shumel Brad⁵

Affiliation:

1. Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA

2. Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

3. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark

4. National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center, Utrecht, Netherlands

5. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

6. Sanofi, Bridgewater, NJ, USA

7. Sanofi Genzyme, Cambridge, MA, USA

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2020.1871463

Reference26 articles.

1. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

2. Japanese guidelines for atopic dermatitis 2017

3. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

4. Guidelines of care for the management of atopic dermatitis

5. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: A systematic review and meta-analysis;Journal of the American Academy of Dermatology;2024-07

2. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP;European Archives of Oto-Rhino-Laryngology;2024-02-12

3. Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience;Respiratory Medicine;2023-10

4. Atopic dermatitis in children and adults;Deutsches Ärzteblatt international;2023-03-31

5. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis;JAMA Dermatology;2023-03-01